BioNTech to Host Innovation Series R&D Day on November 14, 2024
BioNTech SE (Nasdaq: BNTX) has announced its upcoming Innovation Series R&D Day, scheduled for November 14, 2024, at 10:30 a.m. EST (16:30 CET) in New York City. The event will feature presentations from the company's leadership team, who will outline corporate strategy and provide updates on clinical pipeline progress.
The event will be accessible to investors, analysts, and the public through an online webcast. Presentation materials will be available on BioNTech's website, with the webcast replay remaining accessible for one year after the event.
BioNTech SE (Nasdaq: BNTX) ha annunciato il suo prossimo Innovation Series R&D Day, programmato per il 14 novembre 2024, alle 10:30 EST (16:30 CET) a New York City. L'evento presenterà interventi del team di leadership dell'azienda, che illustreranno la strategia aziendale e forniranno aggiornamenti sui progressi della pipeline clinica.
L'evento sarà accessibile a investitori, analisti e al pubblico tramite una webcast online. I materiali delle presentazioni saranno disponibili sul sito web di BioNTech, con la registrazione della webcast accessibile per un anno dopo l'evento.
BioNTech SE (Nasdaq: BNTX) ha anunciado su próximo Día de I+D de la Serie de Innovación, programado para el 14 de noviembre de 2024, a las 10:30 a.m. EST (16:30 CET) en Nueva York. El evento contará con presentaciones del equipo de liderazgo de la empresa, que describirá la estrategia corporativa y proporcionará actualizaciones sobre el progreso de la pipeline clínica.
El evento será accesible para inversores, analistas y el público a través de una transmisión en línea. Los materiales de las presentaciones estarán disponibles en el sitio web de BioNTech, y la repetición de la transmisión estará accesible durante un año después del evento.
BioNTech SE (Nasdaq: BNTX)는 2024년 11월 14일 오전 10시 30분 EST (16시 30분 CET)에 뉴욕에서 예정된 혁신 시리즈 연구개발의 날을 발표했습니다. 이 행사에서는 회사의 리더십 팀이 발표를 진행하며, 기업 전략을 설명하고 임상 파이프라인 진행 상황에 대한 업데이트를 제공합니다.
이 행사는 투자자, 분석가 및 일반 대중이 온라인 웹캐스트를 통해 접근할 수 있습니다. 발표 자료는 BioNTech의 웹사이트에서 제공되며, 웹캐스트 재생은 행사 후 1년 동안 접근 가능합니다.
BioNTech SE (Nasdaq: BNTX) a annoncé sa prochaine Journée R&D de la Série Innovation, prévue pour le 14 novembre 2024 à 10h30 EST (16h30 CET) à New York. L'événement comprendra des présentations de l'équipe de direction de l'entreprise, qui exposera la stratégie d'entreprise et fournira des mises à jour sur les progrès de son pipeline clinique.
L'événement sera accessible aux investisseurs, analystes et au public via un webinaire en ligne. Les documents de présentation seront disponibles sur le site Web de BioNTech, et le replay du webinaire sera accessible pendant un an après l'événement.
BioNTech SE (Nasdaq: BNTX) hat seinen bevorstehenden Innovation Series F&E Tag angekündigt, der am 14. November 2024 um 10:30 Uhr EST (16:30 CET) in New York City stattfinden wird. Die Veranstaltung wird Präsentationen des Führungsteams des Unternehmens beinhalten, das die Unternehmensstrategie skizzieren und Fortschritte in der klinischen Pipeline mitteilen wird.
Die Veranstaltung wird für Investoren, Analysten und die Öffentlichkeit über einen Online-Webcast zugänglich sein. Präsentationsmaterialien werden auf der Website von BioNTech verfügbar sein, und die Wiederholung des Webcasts wird für ein Jahr nach der Veranstaltung zugänglich bleiben.
- None.
- None.
MAINZ, Germany, October 31, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time (16:30 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S.
On the day, BioNTech’s leadership team will provide an overview of the Company’s corporate strategy and clinical progress across its pipeline.
Investors, analysts and the interested public are invited to join the event online via this link.
A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company’s website for one year following the call. The public may also access the presentation slides via the “Events & Presentations” page of the Investor Relations section of the Company’s website at www.BioNTech.com.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com.
CONTACTS
Investor Relations
Michael Horowicz
Investors@biontech.de
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
FAQ
When is BioNTech's (BNTX) Innovation Series R&D Day in 2024?
How can investors access BioNTech's (BNTX) R&D Day presentation materials?
Will BioNTech's (BNTX) R&D Day 2024 be available for replay?
What topics will be covered at BioNTech's (BNTX) R&D Day 2024?
